Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

myRocky vs Wellorithm

myRocky
Graded #487

Higher grade

vs+2.8999999999999986
Wellorithm
Graded #486

Lower grade

The verdict

myRocky takes it — 51.4/100 to 48.5/100.

myRocky grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. myRocky is a Canadian-incorporated multi-product telehealth platform (Rocky Health Inc., Ontario) that markets brand-name GLP-1s — Ozempic, Mounjaro, and Wegovy — to US patients, with no compounded products.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valuemyRocky +4
34
30
Dose & formulationWellorithm +39
53
92
Clinical oversightmyRocky +36
64
28
Labs & monitoringmyRocky +12
52
40
FulfillmentmyRocky +8
70
62
Contract termsWellorithm +4
41
45
myRocky · left barWellorithm · right bar

The numbers

MetricmyRockyWellorithm
WeighScore51.4/10048.5/100
GradeCC
Scorecard rank#487#486
SemaglutideNot disclosedPricing not published
TirzepatideNot disclosedPricing not published
CoverageCoverage not published49 states (not Louisiana)
Brand-name accessYesYes
Oral / sublingualInjection onlyYes
myRocky

Graded #487 · C

Strengths

  • Brand-name FDA-approved GLP-1s (Ozempic, Mounjaro, Wegovy) on one platform — no compounded-product risk
  • LegitScript Approved
  • 42-state coverage with an 8-state expansion roadmap published
  • Multi-product platform for patients managing GLP-1 plus sexual health, hair loss, or mental health on one subscription

Where it loses points

  • Expensive stacked fees: $99 consult + $99/mo program fee + ~$1,409/mo medication = ~$1,508/mo
  • Canadian incorporation (Rocky Health Inc., Mississauga, ON) — verify your state's prescriber holds an active US license
  • Listed pharmacy is a Canadian community pharmacy; US-fulfillment supply chain not transparent
  • Brand-only — no compounded option for cost-sensitive patients
  • $1,409/mo Ozempic is near retail; compare NovoCare ($349/mo Wegovy pen) or LillyDirect ($449–$699/mo Zepbound)
Wellorithm

Graded #486 · C

Strengths

  • Both molecules in BOTH routes — compounded semaglutide and tirzepatide as injections and as oral dissolving tablets
  • Four branded pens on the same account: Mounjaro, Ozempic, Wegovy and Zepbound
  • Sermorelin offered alongside the GLP-1 line
  • 24/7 phone support on a published number

Where it loses points

  • No price appears anywhere on the public site — /pricing 404s and every product CTA leads to a 2-minute intake quiz, so no cost can be compared before signing up
  • The site contradicts itself on coverage: the homepage says "Serving All 50 States" while its own FAQ says 49 states and excludes Louisiana
  • The four clinicians presented as "board-certified obesity specialists" are listed as Cardiac Surgery, Pediatric Clinic, Gynecology and Cardiac Surgery — none in obesity medicine
  • "100% Customer Satisfaction" is stated as a headline fact and is not a substantiable claim

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard